{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:48Z","timestamp":1792271388635,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jhep.2017.03.039","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T07:32:48Z","timestamp":1492068768000},"page":"263-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":275,"title":["Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis"],"prefix":"10.1016","volume":"67","author":[{"given":"Paul Y.","family":"Kwo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Poordad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Asatryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Wyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Felizarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict","family":"Maliakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Overcash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra S.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa I.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico J.","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.03.039_b0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm","volume":"21","author":"Razavi","year":"2014","journal-title":"J Viral Hepatitis"},{"key":"10.1016\/j.jhep.2017.03.039_b0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.039_b0015","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.039_b0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12646","article-title":"Review article: HCV genotype 3 - the new treatment challenge","volume":"39","author":"Ampuero","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.039_b0025","series-title":"EPCLUSA (sofosbuvir and velpatasvir) [package insert]","author":"Sciences","year":"2016"},{"key":"10.1016\/j.jhep.2017.03.039_b0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/liv.13027","article-title":"Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives","volume":"36","author":"Asselah","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.039_b0035","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.039_b0040","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2017.03.039_b0045","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/apt.12625","article-title":"The impact of hepatitis C burden: an evidence-based approach","volume":"39","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.03.039_b0050","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.02264-15","article-title":"Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection","volume":"60","author":"Lawitz","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.03.039_b0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02558-16","article-title":"In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir","author":"Ng","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.03.039_b0060","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.07.020","article-title":"High efficacy of ABT-493 and ABT-530 in patients with HCV genotype 1 or 3 infection and compensated cirrhosis","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.039_b0065","article-title":"Potent antiviral activity of direct-acting antivirals, ABT-493 and ABT-530, with 3-day monotherapy for hepatitis C genotype 1 infection","author":"Lawitz","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.03.039_b0070","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.03.039_b0075","unstructured":"OLYSIO (simeprevir) [package insert]. Janssen Therapeutics. Titusville, NJ2013."},{"key":"10.1016\/j.jhep.2017.03.039_b0080","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.02524-15","article-title":"In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir","volume":"60","author":"Cheng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.03.039_b0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2017.03.039_b0090","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","article-title":"Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.03.039_b0095","unstructured":"Administration FaD. Division of Antiviral Products Virology Review, NDA 208341. 2015."},{"key":"10.1016\/j.jhep.2017.03.039_b0100","article-title":"In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of HCV NS5A","author":"Krishnan","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.03.039_b0105","first-page":"183","article-title":"High SVRRates with ABT-493 + ABT-530 co-administered for 8 weeks in non-cirrhotic patients with HCV genotype 3 infection","volume":"64","author":"Muir","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.039_b0110","unstructured":"Hassanein T, Wyles, D., Wang, S. et al. Glecaprevir\/Pibrentasvir Demonstrates High SVR Rates in Patients with HCV Genotype 2, 4, 5, or 6 Infection without Cirrhosis Following an 8-Week Treatment Duration: SURVEYOR-II, Part 4.). Paper presented at: The Liver Meeting 2016; Boston, MA."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817302118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817302118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T14:55:23Z","timestamp":1535900123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817302118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0168827817302118"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.03.039","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}